Alizapride

From Drugs Prescribing Information
Jump to: navigation, search

Contents

[edit] BRAND NAMES

[edit] STRUCTURE

Alizapride.jpg

[edit] MECHANISM OF ACTION

The anti-emetic action of Alizapride is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS)—this action prevents nausea and vomiting triggered by most stimuli. Structurally similar to metoclopramide and, therefore, shares similar other atributres related to emesis and prokinetics.

[edit] INDICATIONS

Alizapride is used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.

[edit] DOSAGE

The treatment duration should not exceed one week.

Oral administration: 100-200 mg per day in divided doses

Parenteral administration:

  • nausea and vomiting in pre-or post-operative, 50-200 mg, usually intramuscularly within 24 hours.
  • Nausea and vomiting during chemotherapy: 100 mg intravenously 20-30 minutes prior to chemotherapy treatment, followed by 50-100 mg intramuscularly 4-8 hours after the end of chemotherapy.

[edit] CONTRAINDICATIONS

  • hypersensitivity to alizapride.
  • in subjects having previously presented tardive dyskinesia following neuroleptic treatment,
  • in subjects with known or suspected pheochromocytoma, severe hypertensive crisis having been reported in these patients when treated with antidopaminergic drugs, including certain benzamides,
  • in combination with medicinal products containing levodopa
  • during pregnancy

[edit] PRECAUTIONS

The simultaneous ingestion of alcoholic beverages is not recommended.

Epileptic subjects: monitoring must be increased since Alizapride can lower the epileptogenic threshold.

The onset of a malignant syndrome (hyperthermia, muscle rigidity, neurovegetative disturbances, altered consciousness, elevated CPK levels) is possible. Precautions must be taken in the event of hyperthermia or other symptoms of malignant syndrome and treatment must be stopped immediately if malignant neuroleptic syndrome is suspected.

[edit] INTERACTIONS

[edit] PREGNANCY AND LACTATION

Pregnancy: Although the results of studies conducted in animals have not revealed any teratogenic effects, as a precautionary measure in the absence of any epidemiological studies, this medicinal product should not be prescribed during pregnancy.

Breast-feeding: In the absence of any studies on passage into breast milk, caution is required in breastfeeding women.

[edit] SIDE EFFECTS

These are particularly observed with high dosages:

Central nervous system and psychiatric signs

  • Extrapyramidal symptoms, particularly in children and young adults, even after just one dose of the medicine. These involve acute dystonia, which can be manifested by facial spasms, involuntary movements, torticollis. The symptoms generally disappear spontaneously and completely when treatment is stopped.
  • Tardive dyskinesia, which may be observed in the event of prolonged treatment.
  • Drowsiness, dizziness, headaches, insomnia

Gastrointestinal disturbances

  • Diarrhoea.

Endocrine effects

  • Amenorrhoea, galactorrhoea, gynaecomastia, hyperprolactinaemia.

General disturbances

  • Allergic reactions, including anaphylactic reactions.

Cardiovascular disturbances

  • Orthostatic hypotension.

[edit] RELATED LINKS

[edit] BIBLIOGRAPHY

[edit] REFERENCES

Antiemetics
5-HT3 receptor antagonists Dolasetron   Granisetron   Ondansetron   Palonosetron   Tropisetron
Dopamine antagonists Alizapride   Bromopride   Clebopride   Domperidone   Metoclopramide   Prochlorperazine   Thiethylperazine
H1 antagonists Dimenhydrinate   Meclizine
NK1 receptor antagonists‎ Aprepitant   Fosaprepitant   Maropitant
Motion sickness‎ Cinnarizine   Dimenhydrinate   Meclizine   Meclizine/Pyridoxine   Scopolamine (Patch)
Pregnancy Meclizine/Pyridoxine   Ondansetron
Veterinary Maropitant